淋巴瘤
医学
伯基特淋巴瘤
靶向治疗
癌症研究
化学免疫疗法
免疫学
PI3K/AKT/mTOR通路
肿瘤科
内科学
癌症
细胞凋亡
生物
美罗华
生物化学
作者
Suheil Albert Atallah‐Yunes,Thomas M. Habermann,Arushi Khurana
摘要
Multiagent chemoimmunotherapy remains the standard of care treatment for Burkitt lymphoma leading to a cure in the majority of cases. However, frontline treatment regimens are associated with a significant risk of treatment related toxicity especially in elderly and immunocompromised patients. Additionally, prognosis remains dismal in refractory/relapsed Burkitt lymphoma. Thus, novel therapies are required to not only improve outcomes in relapsed/refractory Burkitt lymphoma but also minimize frontline treatment related toxicities. Recurrent genomic changes and signalling pathway alterations that have been implicated in the Burkitt lymphomagenesis include cell cycle dysregulation, cell proliferation, inhibition of apoptosis, epigenetic dysregulation and tonic B-cell receptor-phosphatidylinositol 3-kinase (BCR-PI3K) signalling. Here, we will discuss novel targeted therapy approaches using small molecule inhibitors that could pave the way to the future treatment landscape based on the understanding of recurrent genomic changes and signalling pathway alterations in the lymphomagenesis of adult Burkitt lymphoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI